keyword
MENU ▼
Read by QxMD icon Read
search

RECIST

keyword
https://www.readbyqxmd.com/read/28934812/prediction-of-pathological-complete-response-to-neoadjuvant-chemotherapy-for-primary-breast-cancer-comparing-interim-ultrasound-shear-wave-elastography-and-mri
#1
Andrew Evans, Patsy Whelehan, Alastair Thompson, Colin Purdie, Lee Jordan, Jane Macaskill, Shelley Waugh, Frances Fuller-Pace, Katrin Brauer, Sarah Vinnicombe
Background Prediction of pathological complete response (pCR) of primary breast cancer to neoadjuvant chemotherapy (NACT) may influence planned surgical approaches in the breast and axilla. The aim of this project is to assess the value of interim shear wave elastography (SWE), ultrasound (US) and magnetic resonance imaging (MRI) after 3 cycles in predicting pCR. Methods 64 patients receiving NACT had baseline and interim US, SWE and MRI examinations. The mean lesion stiffness at SWE, US and MRI diameter was measured at both time points...
September 21, 2017: Ultraschall in der Medizin
https://www.readbyqxmd.com/read/28932641/response-to-first-line-chemotherapy-regimen-is-associated-with-efficacy-of-nivolumab-in-non-small-cell-lung-cancer
#2
Courèche-Guillaume Kaderbhai, Corentin Richard, Jean David Fumet, Anne Aarnink, Sandra Ortiz-Cuaran, Maurice Pérol, Pascal Foucher, Bruno Coudert, Laure Favier, Aurélie Lagrange, Emeric Limagne, Romain Boidot, Sylvain Ladoire, Michel Poudenx, Marius Ilie, Paul Hofman, Pierre Saintigny, François Ghiringhelli
Nivolumab, an anti PD-1 checkpoint inhibitor has demonstrated efficacy in metastatic non-small-cell lung cancer (NSCLC) patients after failure to standard chemotherapy. Standard chemotherapy agents could promote antitumor immune response. We thus examined whether the response to first line chemotherapy could impact on nivolumab benefit. One hundred and 15 patients with NSCLC were included in this retrospective study from 4 different French centers. Forty-three squamous cell carcinomas (SCC), and 72 non-SCC received nivolumab between 2015 and 2016 (3 mg/kg IV Q2W)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28932630/the-safety-efficacy-and-treatment-outcomes-of-a-combination-of-low-dose-decitabine-treatment-in-patients-with-recurrent-ovarian-cancer
#3
Yan Zhang, Qian Mei, Yang Liu, Xiang Li, Malcolm V Brock, Meixia Chen, Liang Dong, Lu Shi, Yao Wang, Mingzhou Guo, Jing Nie, Weidong Han
Purpose: DNA demethylating agents have shown clinical effectiveness in hematological and solid tumors. This trial tested the safety, efficacy, and treatment outcomes of decitabine-based chemotherapy or combined with immunotherapy in recurrent ovarian cancer patients. Patients and methods: Fifty-five patients with recurrent ovarian cancer were enrolled and 52 were assessable for clinical response and survival. Patients either received 5-d decitabine treatment, followed by reduced-dose of paclitaxel/carboplatin administration (DTC cohort), or the aforementioned regimen combined with cytokine-induced killer cells therapy (DTC+CIK cohort)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28928422/role-of-chemotherapy-in-dedifferentiated-liposarcoma-of-the-retroperitoneum-defining-the-benefit-and-challenges-of-the-standard
#4
J A Livingston, D Bugano, A Barbo, H Lin, J E Madewell, W L Wang, A J Lazar, W W Tseng, C L Roland, B W Feig, R Pollock, A P Conley, R S Benjamin, S Patel, N Somaiah
Benefit from chemotherapy for well-differentiated/de-differentiated (WD/DD) liposarcomas has been reported to be minimal, however traditional response criteria may not adequately capture positive treatment effect. In this study, we evaluate benefit from first-line chemotherapy and characterize imaging response characteristics in patients with retroperitoneal (RP) WD/DD liposarcoma treated at The University of Texas MD Anderson Cancer Center. Response was assessed using RECIST (Response Evaluation Criteria in Solid Tumors) and an exploratory analysis of vascular response was characterized...
September 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28921872/first-line-therapy-with-dacomitinib-an-orally-available-pan-her-tyrosine-kinase-inhibitor-for-locally-advanced-or-metastatic-penile-squamous-cell-carcinoma-results-of-an-open-label-single-arm-single-center-phase-2-study
#5
A Necchi, S Lo Vullo, F Perrone, D Raggi, P Giannatempo, G Calareso, N Nicolai, L Piva, D Biasoni, M Catanzaro, T Torelli, S Stagni, E Togliardi, M Colecchia, A Busico, A Gloghini, A Testi, L Mariani, R Salvioni
OBJECTIVE: To harness the frontline therapy in advanced penile squamous cell carcinoma (PSCC), for which chemotherapy exerts moderate activity but poor efficacy. Dacomitinib is an irreversible, pan-epidermal growth factor receptor (HER) inhibitor. PATIENTS AND METHODS: In a phase 2 study (NCT01728233), patients received dacomitinib 45 mg/day, orally, continuously. Inclusion criteria were SCC histology, clinical stage N2-3 or M1 (TNM 2009), and no prior chemotherapy administration...
September 16, 2017: BJU International
https://www.readbyqxmd.com/read/28917596/response-rate-to-chemotherapy-after-immune-checkpoint-inhibition-in-metastatic-urothelial-cancer
#6
Bernadett Szabados, Nick van Dijk, Yen Zhi Tang, Michiel van der Heijden, Akhila Wimalasingham, Alfonso Gomez de Liano, Simon Chowdhury, Simon Hughes, Sarah Rudman, Mark Linch, Thomas Powles
Immune checkpoint inhibitors (ICIs) are active in metastatic urothelial carcinoma (MUC). They have joined chemotherapy (CT) as a standard of care. Here, we investigate the activity of CT after progression on ICIs. Two cohorts of sequential patients with MUC were described (n=28). Cohort A received first-line ICIs followed by CT after progression. Cohort B received CT after failure of first-line platinum-based CT followed by ICIs. Response rate (RR) to CT was assessed using Response Evaluation Criteria in Solid Tumors (RECIST v1...
September 13, 2017: European Urology
https://www.readbyqxmd.com/read/28916623/efficacy-of-radioembolization-with-holmium-166-microspheres-in-salvage-patients-with-liver-metastases-a-phase-2-study
#7
Jip F Prince, Maurice A A J van den Bosch, J F W Nijsen, Maarten L J Smits, Andor F van den Hoven, Stavros Nikolakopoulos, Frank J Wessels, Rutger C G Bruijnen, Manon Braat, Bernard A Zonnenberg, Marnix Lam
Rationale: Radioembolization of liver malignancies with holmium-166 (166Ho) microspheres has been shown safe in a phase 1 dose-escalation study. The purpose of this study was to investigate the efficacy of 166Ho radioembolization. Methods: In this prospective single-arm study, 56 patients were enrolled, all with liver metastases refractory to systemic therapy and ineligible for surgical resection. Radioembolization was performed with a projected average absorbed dose of 60 Gy to the liver (equal to 3.8 GBq/kg liver tissue)...
September 15, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28903445/predicting-clinical-benefit-from-everolimus-in-patients-with-advanced-solid-tumors-the-cpct-03-study
#8
Fleur Weeber, Geert A Cirkel, Marlous Hoogstraat, Sander Bins, Christa G M Gadellaa-van Hooijdonk, Salo Ooft, Erik van Werkhoven, Stefan M Willems, Marijn van Stralen, Wouter B Veldhuis, Nicolle J M Besselink, Hugo M Horlings, Neeltje Steeghs, Maja J de Jonge, Marlies H G Langenberg, Lodewyk F A Wessels, Edwin P J G Cuppen, J H Schellens, Stefan Sleijfer, Martijn P Lolkema, Emile E Voest
BACKGROUND: In this study, our aim was to identify molecular aberrations predictive for response to everolimus, an mTOR inhibitor, regardless of tumor type. METHODS: To generate hypotheses about potential markers for sensitivity to mTOR inhibition, drug sensitivity and genomic profiles of 835 cell lines were analyzed. Subsequently, a multicenter study was conducted. Patients with advanced solid tumors lacking standard of care treatment options were included and underwent a pre-treatment tumor biopsy to enable DNA sequencing of 1,977 genes, derive copy number profiles and determine activation status of pS6 and pERK...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28894897/peptide-receptor-radionuclide-therapy-prrt-in-european-neuroendocrine-tumour-society-enets-grade-3-g3-neuroendocrine-neoplasia-nen-a-single-institution-retrospective-analysis
#9
Sue Ping Thang, Mei Sim Lung, Grace Kong, Michael S Hofman, Jason Callahan, Michael Michael, Rodney J Hicks
PURPOSE: Grade 3 NENs are aggressive tumours with poor prognosis. PRRT+/- radiosensitising chemotherapy is a potential treatment for disease with high somatostatin receptor (SSTR) expression without spatially discordant FDG-avid disease. We retrospectively evaluated the efficacy of PRRT in G3 NEN. METHODS: Kaplan-Meier estimation was used to determine progression-free survival (PFS) and overall survival (OS) defined from start of PRRT. Subgroup analysis was performed for patients with Ki-67 ≤ 55% and >55%...
September 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28893303/contrast-enhanced-spectral-mammography-in-neoadjuvant-chemotherapy-monitoring-a-comparison-with-breast-magnetic-resonance-imaging
#10
Valentina Iotti, Sara Ravaioli, Rita Vacondio, Chiara Coriani, Sabrina Caffarri, Roberto Sghedoni, Andrea Nitrosi, Moira Ragazzi, Elisa Gasparini, Cristina Masini, Giancarlo Bisagni, Giuseppe Falco, Guglielmo Ferrari, Luca Braglia, Alberto Del Prato, Ivana Malavolti, Vladimiro Ginocchi, Pierpaolo Pattacini
BACKGROUND: Neoadjuvant-chemotherapy (NAC) is considered the standard treatment for locally advanced breast carcinomas. Accurate assessment of disease response is fundamental to increase the chances of successful breast-conserving surgery and to avoid local recurrence. The purpose of this study was to compare contrast-enhanced spectral mammography (CESM) and contrast-enhanced-MRI (MRI) in the evaluation of tumor response to NAC. METHODS: This prospective study was approved by the institutional review board and written informed consent was obtained...
September 11, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28892430/characterization-of-pulmonary-metastases-in-children-with-hepatoblastoma-treated-on-children-s-oncology-group-protocol-ahep0731-the-treatment-of-children-with-all-stages-of-hepatoblastoma-a-report-from-the-children-s-oncology-group
#11
Allison F O'Neill, Alexander J Towbin, Mark D Krailo, Caihong Xia, Yun Gao, M Beth McCarville, Rebecka L Meyers, Eugene D McGahren, Greg M Tiao, Stephen P Dunn, Max R Langham, Christopher B Weldon, Milton J Finegold, Sarangarajan Ranganathan, Wayne L Furman, Marcio Malogolowkin, Carlos Rodriguez-Galindo, Howard M Katzenstein
Purpose To determine whether the pattern of lung nodules in children with metastatic hepatoblastoma (HB) correlates with outcome. Methods Thirty-two patients with metastatic HB were enrolled on Children's Oncology Group Protocol AHEP0731 and treated with vincristine and irinotecan (VI). Responders to VI received two additional cycles of VI intermixed with six cycles of cisplatin/fluorouracil/vincristine/doxorubicin (C5VD), and nonresponders received six cycles of C5VD alone. Patients were imaged after every two cycles and at the conclusion of therapy...
September 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28885700/historical-time-to-disease-progression-and-progression-free-survival-in-patients-with-recurrent-refractory-neuroblastoma-treated-in-the-modern-era-on-children-s-oncology-group-early-phase-trials
#12
Wendy B London, Rochelle Bagatell, Brenda J Weigel, Elizabeth Fox, Dongjing Guo, Collin Van Ryn, Arlene Naranjo, Julie R Park
BACKGROUND: Early-phase trials in patients with recurrent neuroblastoma historically used an objective "response" of measureable disease (Response Evaluation Criteria In Solid Tumors [RECIST], without bone/bone marrow assessment) to select agents for further study. Historical cohorts may be small and potentially biased; to the authors' knowledge, disease recurrence studies from international registries are outdated. Using a large recent cohort of patients with recurrent/refractory neuroblastoma from Children's Oncology Group (COG) modern-era early-phase trials, the authors determined outcome and quantified parameters for designing future studies...
September 8, 2017: Cancer
https://www.readbyqxmd.com/read/28881847/to-predict-the-radiosensitivity-of-nasopharyngeal-carcinoma-using-intravoxel-incoherent-motion-mri-at-3-0-t
#13
Wen Bo Chen, Bin Zhang, Long Liang, Yu Hao Dong, Guan Hui Cai, Chang Hong Liang, Bo Wen Lan, Shui Xing Zhang
PURPOSE: To investigate intravoxel incoherent motion (IVIM) MRI for evaluating the sensitivity of radiotherapy on nasopharyngeal carcinoma (NPC). RESULTS: The reproducibility between intra-observer and inter-observer was relatively good. D (0.72×10(-3) mm(2)/s±0.14 vs. 0.54×10(-3) mm(2)/s±0.23; P < 0.001) and D* (157.92×10(-3) mm(2)/s±15.21 vs. 120.36×10(-3) mm(2)/s±10.22; P < 0.0001) were significantly higher in effective group than poor-effective group, whereas the difference of f (18...
August 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28870953/role-of-densitometric-criteria-in-evaluation-of-effectiveness-of-antiangiogenic-therapies-in-metastatic-colorectal-cancer-an-italian-clinical-experience
#14
Giuseppe Cicero, Giuseppe Lo Re, Rossella DE Luca, Federica Vernuccio, Dario Picone, Massimo Midiri, Roberto Lagalla
BACKGROUND/AIM: To evaluate the role of densitometric criterion using the Choi Criteria in the assessment of the response to antiangiogenic treatments of metastatic colorectal cancer (mCRC) compared to the RECIST criteria. PATIENTS AND METHODS: Fifty-four patients (mean age=50.6 years) affected by advanced colorectal cancer and with hepatic and possibly peritoneal and pulmonary metastases, that can be treated with bevacizumab, were prospectively evaluated by computerized tomography (CT) scan...
September 2017: Anticancer Research
https://www.readbyqxmd.com/read/28869396/stereotactic-hypofractionated-body-radiation-therapy-as-an-effective-treatment-for-lymph-node-metastases-from-colorectal-cancer-an-institutional-retrospective-analysis
#15
Ciro Franzese, Antonella Fogliata, Tiziana Comito, Angelo Tozzi, Cristina Iftode, Elena Clerici, Davide Franceschini, Pierina Navarria, Anna Maria Ascolese, Lucia Di Brina, Fiorenza De Rose, Giuseppe R D'Agostino, Luca Cozzi, Marta Scorsetti
OBJECTIVE: The colorectal cancer (CRC) might present loco-regional recurrence, including lymph-node metastasis. Stereotactic body radiotherapy (SBRT) is a non-invasive and well-tolerated ablative treatment. Aim of the present study is to evaluate efficacy and toxicity of SBRT with volumetric modulated arc therapy (VMAT) in this setting. METHODS: 35 patients presenting a total of 47 nodal recurrences from CRC, treated with VMAT-SBRT from 2008 to 2015, were selected...
September 4, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28864950/correlation-of-early-pet-findings-with-tumor-response-to-molecular-targeted-agents-in-patients-with-advanced-driver-mutated-non-small-cell-lung-cancer
#16
Tomonobu Koizumi, Toshirou Fukushima, Daisuke Gomi, Takashi Kobayashi, Nodoka Sekiguchi, Keiko Mamiya, Kazunari Tateishi, Akane Katou, Kazuhiro Oguchi
Recent advances in positron emission tomography with fluorine-18-fluorodeoxyglucose (FDG-PET) have facilitated not only the diagnosis and staging of lung cancer, but also the prediction of treatment outcome. The present study was designed to assess the usefulness of early FDG-PET examination for predicting subsequent tumor size reduction in response to molecular targeted agents in metastatic non-small cell lung cancer (NSCLC) with sensitive gene anomalies. I. In 29 targeted lesions of 10 NSCLC patients, changes in FDG uptake before and on day 7 after the initiation of molecular targeted therapy (gefitinib, n = 7; crizotinib, n = 3) were compared with subsequent radiographic tumor size reduction by RECIST...
September 1, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28860886/clinical-staging-of-malignant-pleural-mesothelioma-current-perspectives
#17
REVIEW
Maria Bonomi, Costantino De Filippis, Egesta Lopci, Letizia Gianoncelli, Giovanna Rizzardi, Eleonora Cerchiaro, Luigi Bortolotti, Alessandro Zanello, Giovanni Luca Ceresoli
Malignant pleural mesothelioma (MPM) is a disease with limited therapeutic options, the management of which is still controversial. Diagnosis is usually made by thoracoscopy, which allows multiple biopsies with histological subtyping and is indicated for staging purposes in surgical candidates. The recommended and recently updated classification for clinical use is the TNM staging system established by the International Mesothelioma Interest Group and the International Association for the Study of Lung Cancer, which is based mainly on surgical and pathological variables, as well as on cross-sectional imaging...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28859644/predictive-value-of-c-reactive-protein-in-patients-treated-with-sunitinib-for-metastatic-clear-cell-renal-cell-carcinoma
#18
Martin Pilskog, Christian Beisland, Lars A Akslen, Leif Bostad, Åse Haug, Daniel Heinrich, Karin M Hjelle, Oddbjørn Straume
BACKGROUND: Sunitinib has become mainstay first line treatment for patients with metastatic renal clear cell carcinoma (mRCC). Still, useful predictive markers of response are lacking and urgently needed for clinical decision making. METHODS: In the present study we investigated the predictive value of standard serum markers as well as clinical markers, including C-reactive protein (CRP), Neutrophil to Lymphocyte ratio (NLR) and early hypertension (eHTN) in an unselected prospective patient population treated with sunitinib for mRCC...
August 31, 2017: BMC Urology
https://www.readbyqxmd.com/read/28859059/phase-1-safety-pharmacokinetic-and-pharmacodynamic-study-of-the-cyclin-dependent-kinase-inhibitor-dinaciclib-administered-every-three-weeks-in-patients-with-advanced-malignancies
#19
Monica M Mita, Alain C Mita, Jennifer L Moseley, Jennifer Poon, Karen A Small, Ying-Ming Jou, Paul Kirschmeier, Da Zhang, Yali Zhu, Paul Statkevich, Kamelesh K Sankhala, John Sarantopoulos, James M Cleary, Lucian R Chirieac, Scott J Rodig, Rajat Bannerji, Geoffrey I Shapiro
BACKGROUND: Dinaciclib is a potent inhibitor of cell cycle and transcriptional cyclin-dependent kinases. This Phase 1 study evaluated the safety, tolerability and pharmacokinetics of various dosing schedules of dinaciclib in advanced solid tumour patients and assessed Pharmacodynamic and preliminary anti-tumour activity. METHODS: In part 1, patients were enrolled in escalating cohorts of 2-h infusions administered once every 3 weeks, utilising an accelerated titration design until a recommended phase 2 dose (RP2D) was defined...
August 31, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28856177/intravoxel-incoherent-motion-ivim-histogram-biomarkers-for-prediction-of-neoadjuvant-treatment-response-in-breast-cancer-patients
#20
Gene Y Cho, Lucas Gennaro, Elizabeth J Sutton, Emily C Zabor, Zhigang Zhang, Dilip Giri, Linda Moy, Daniel K Sodickson, Elizabeth A Morris, Eric E Sigmund, Sunitha B Thakur
OBJECTIVE: To examine the prognostic capabilities of intravoxel incoherent motion (IVIM) metrics and their ability to predict response to neoadjuvant treatment (NAT). Additionally, to observe changes in IVIM metrics between pre- and post-treatment MRI. METHODS: This IRB-approved, HIPAA-compliant retrospective study observed 31 breast cancer patients (32 lesions). Patients underwent standard bilateral breast MRI along with diffusion-weighted imaging before and after NAT...
2017: European Journal of Radiology Open
keyword
keyword
18088
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"